PDF(Pubmed)
Abstract：
Photoimmunotherapy is a novel cancer treatment that recently became covered by national health insurance in Japan, but treatment decision-making remains challenging for unresectable advanced or recurrent head and neck cancer. We aimed to clarify the characteristics of patients for whom photoimmunotherapy was indicated by a retrospective chart review. Patients aged ≥20 years diagnosed with advanced or recurrent head and neck cancer who started receiving systemic therapy at the National Cancer Center Hospital East from January 2016 through December 2020 were retrospectively analyzed. Before and after first-line systemic therapy, patients were classified into 3 groups according to eligibility for photoimmunotherapy: eligible, potentially eligible, and ineligible. In total, of 246 patients evaluated-194 after exclusions were analyzed-108 were deemed ineligible for treatment. Of the remaining 86 patients, 8 were considered potentially eligible and 9 eligible. Of the nine eligible patients, four became ineligible after receiving first-line systemic therapy due to disease progression. Our results suggest that the indication of photoimmunotherapy should be considered before, during, and after systemic therapy for unresectable locally advanced or recurrent head and neck cancer.
摘要：
光免疫疗法是一种新型的癌症治疗方法，最近在日本被国民健康保险所覆盖。但对于无法切除的晚期或复发性头颈部癌,治疗决策仍具有挑战性.我们旨在通过回顾性图表回顾来阐明光免疫疗法的患者的特征。回顾性分析2016年1月至2020年12月在美国国家癌症中心医院东部开始接受全身治疗的年龄≥20岁的晚期或复发性头颈部癌患者。一线全身治疗前后，根据光免疫疗法的资格将患者分为3组:可能符合条件，并没有资格。总的来说,对排除后评估的246例患者-194例进行了分析-108例被认为不适合接受治疗.在剩下的86名患者中，8人被认为是潜在合格的，9人被认为是合格的。在九个合格的病人中，由于疾病进展,4人在接受一线全身治疗后不合格.我们的结果表明，光免疫疗法的适应症应该被考虑之前，during,以及在无法切除的局部晚期或复发性头颈部癌症的全身治疗后。
